MEDNAX Inc (NYSE:MD) Expected to Post Quarterly Sales of $881.50 Million

Analysts predict that MEDNAX Inc (NYSE:MD) will post $881.50 million in sales for the current quarter, Zacks reports. Eight analysts have issued estimates for MEDNAX’s earnings. The lowest sales estimate is $843.18 million and the highest is $928.24 million. MEDNAX reported sales of $915.92 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 3.8%. The business is scheduled to issue its next earnings report on Thursday, August 1st.

According to Zacks, analysts expect that MEDNAX will report full-year sales of $3.57 billion for the current fiscal year, with estimates ranging from $3.46 billion to $3.74 billion. For the next fiscal year, analysts expect that the company will report sales of $3.73 billion, with estimates ranging from $3.63 billion to $3.92 billion. Zacks’ sales calculations are an average based on a survey of analysts that follow MEDNAX.

MEDNAX (NYSE:MD) last issued its quarterly earnings data on Thursday, May 2nd. The company reported $0.58 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.63 by ($0.05). The firm had revenue of $851.20 million for the quarter, compared to analyst estimates of $906.35 million. MEDNAX had a negative net margin of 1.05% and a positive return on equity of 9.82%. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.89 EPS.

MD has been the subject of a number of analyst reports. Jefferies Financial Group decreased their price objective on shares of MEDNAX from $37.00 to $31.00 and set a “hold” rating for the company in a report on Thursday, April 11th. Zacks Investment Research cut shares of MEDNAX from a “hold” rating to a “sell” rating in a report on Monday, April 22nd. Finally, Citigroup set a $36.00 price objective on shares of MEDNAX and gave the company a “buy” rating in a report on Friday, May 3rd. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $39.33.

Shares of NYSE MD opened at $25.24 on Thursday. The firm has a market capitalization of $2.18 billion, a PE ratio of 7.70, a P/E/G ratio of 0.98 and a beta of 0.65. The firm’s 50 day moving average price is $25.64. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.55 and a current ratio of 2.55. MEDNAX has a 52-week low of $23.05 and a 52-week high of $48.77.

Institutional investors and hedge funds have recently made changes to their positions in the business. Norges Bank bought a new stake in shares of MEDNAX in the fourth quarter worth $34,138,000. Lazard Asset Management LLC lifted its position in shares of MEDNAX by 150.5% in the first quarter. Lazard Asset Management LLC now owns 1,390,670 shares of the company’s stock worth $37,784,000 after purchasing an additional 835,444 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of MEDNAX by 41.5% in the first quarter. Nordea Investment Management AB now owns 2,411,506 shares of the company’s stock worth $65,521,000 after purchasing an additional 707,038 shares in the last quarter. First Trust Advisors LP lifted its position in shares of MEDNAX by 40.8% in the first quarter. First Trust Advisors LP now owns 1,457,639 shares of the company’s stock worth $39,604,000 after purchasing an additional 422,706 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of MEDNAX by 17.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,615,192 shares of the company’s stock worth $86,301,000 after purchasing an additional 381,394 shares in the last quarter. 91.14% of the stock is currently owned by hedge funds and other institutional investors.

About MEDNAX

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Featured Article: What Is An Exchange-Traded Fund (ETF)?

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.